GILEAD SCIENCES, INC.

DEFA14A 1 gild014721-defa14a.htm DEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALS GILEAD SCIENCES, INC. - DEFA 14A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

SCHEDULE 14A

PROXY STATEMENT PURSUANT TO SECTION 14(a)
OF THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. )

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:
	Preliminary Proxy Statement
	Confidential, for Use of the Commission Only (as permitted by Rule 14A-6(E)(2))
	Definitive Proxy Statement
	Definitive Additional Materials
	Soliciting Material under §240.14a-12

GILEAD SCIENCES, INC.

(Name of Registrant as Specified in Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):
	No fee required.
	Fee paid previously with preliminary materials.
	Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.



GILEAD SCIENCES, INC. ATTN: INVESTOR RELATIONS 333 LAKESIDE DRIVE FOSTER CITY, CA 94404		Your Vote Counts! GILEAD SCIENCES, INC. 2026 Annual Meeting Vote by April 29, 2026 8:59 PM PDT


V87556-P47038

You invested in GILEAD SCIENCES, INC. and it’s time to vote!
This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on April 30, 2026, 10:00 a.m. Pacific Daylight Time, virtually at www.virtualshareholdermeeting.com/GILD2026.

Get informed before you vote
You can view the Notice and Proxy Statement and Form 10-K online by visiting www.ProxyVote.com OR you can receive a free paper or email copy of the material(s) by making a request prior to April 16, 2026. To submit a request for a paper or email copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.


	For complete information and to vote, visit www.ProxyVote.com
	Control #

Smartphone users Point your camera here and vote without entering a control number		Vote Virtually at the Meeting* April 30, 2026 10:00 a.m. Pacific Daylight Time
	Virtually at: www.virtualshareholdermeeting.com/GILD2026

*Please check the meeting materials for any special requirements for meeting attendance.

Vote at www.ProxyVote.com

THIS IS NOT A VOTABLE BALLOT

This is an overview of the proposals being presented at the upcoming Annual Meeting. We encourage you to access and review all of the important information contained in the proxy materials before voting. Please follow the instructions on the reverse side to obtain the proxy materials and to vote on these important matters.

Voting Items		Board Recommends
1.	To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified.
	Nominees:
1a.	Jacqueline K. Barton, Ph.D.		For
1b.	Jeffrey A. Bluestone, Ph.D.		For
1c.	Sandra J. Horning, M.D.		For
1d.	Kelly A. Kramer		For
1e.	Ted W. Love, M.D.		For
1f.	Harish Manwani		For
1g.	Daniel P. O’Day		For
1h.	Javier J. Rodriguez		For
1i.	Anthony Welters		For
2.	To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.		For
3.	To approve, on an advisory basis, the compensation of our Named Executive Officers as presented in the Proxy Statement.		For
4.	To approve the amended and restated Gilead Sciences, Inc. 2022 Equity Incentive Plan.		For
5.	To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting.		Against
6.	To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting.		Against
7.	To vote on a stockholder proposal requesting a report on the risks of ESG and DEI executive compensation metrics, if properly presented at the Annual Meeting.		Against

Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”.

V87557-P47038

SEC Form DEFA14A filed by Gilead Sciences Inc.